Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
JACC Heart Fail ; 2(6): 641-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25282031

ABSTRACT

OBJECTIVES: This randomized controlled multicenter trial evaluated coenzyme Q10 (CoQ10) as adjunctive treatment in chronic heart failure (HF). BACKGROUND: CoQ10 is an essential cofactor for energy production and is also a powerful antioxidant. A low level of myocardial CoQ10 is related to the severity of HF. Previous randomized controlled trials of CoQ10 in HF were underpowered to address major clinical endpoints. METHODS: Patients with moderate to severe HF were randomly assigned in a 2-year prospective trial to either CoQ10 100 mg 3 times daily or placebo, in addition to standard therapy. The primary short-term endpoints at 16 weeks were changes in New York Heart Association (NYHA) functional classification, 6-min walk test, and levels of N-terminal pro-B type natriuretic peptide. The primary long-term endpoint at 2 years was composite major adverse cardiovascular events as determined by a time to first event analysis. RESULTS: A total of 420 patients were enrolled. There were no significant changes in short-term endpoints. The primary long-term endpoint was reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003) by intention-to-treat analysis. The following secondary endpoints were significantly lower in the CoQ10 group compared with the placebo group: cardiovascular mortality (9% vs. 16%, p = 0.026), all-cause mortality (10% vs. 18%, p = 0.018), and incidence of hospital stays for HF (p = 0.033). In addition, a significant improvement of NYHA class was found in the CoQ10 group after 2 years (p = 0.028). CONCLUSIONS: Long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events. (Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIomarker status [Brain-Natriuretic Peptide (BNP)], and long-term Outcome [hospitalisations/mortality]; ISRCTN94506234).


Subject(s)
Heart Failure/drug therapy , Ubiquinone/analogs & derivatives , Vitamins/therapeutic use , Biomarkers/metabolism , Chronic Disease , Death, Sudden, Cardiac/etiology , Double-Blind Method , Female , Heart Failure/mortality , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/metabolism , Peptide Fragments/metabolism , Prospective Studies , Ubiquinone/therapeutic use
2.
Scand J Infect Dis ; 43(5): 360-5, 2011 May.
Article in English | MEDLINE | ID: mdl-21306196

ABSTRACT

BACKGROUND: Infection with cytomegalovirus (CMV) remains a potentially serious complication in transplant patients. In this study we explored the risk factors for CMV infection in the 12 months following a solid organ transplantation (n = 242) in patients monitored for CMV infection from 2004 to 2007. METHODS: CMV infection was defined as 2 consecutive quantifiable CMV-polymerase chain reaction (PCR) values or 1 measurement of >3000 copies/ml. Data describing pre- and post-transplantation variables were extracted from electronic health records. Time to CMV infection was investigated using Cox proportional hazards analysis. RESULTS: Overall, 31% (75/242) of solid organ transplant patients developed CMV infection: 4/8 (50.0%) heart, 15/43 (34.9%) liver, 30/89 (33.7%) lung and 26/102 (25.5%) kidney transplant patients. The risk of CMV infection according to donor (D)/recipient (R) CMV serostatus (positive + or negative-) was highest for D+/R-(adjusted hazard ratio 2.6, 95% confidence interval 1.6-4.2) vs D+/R+, and was reduced for D-/R+(adjusted hazard ratio 0.2, 95% confidence interval 0.2-0.8) vs D+/R+. CONCLUSION: Positive donor CMV-serostatus is a major risk factor for CMV-infection in CMV-na ve recipients, but also in recipients with positive CMV-serostatus. Conversely, if donor is CMV serostatus is negative, the risk of CMV infection is low, irrespective of recipients CMV-serostatus. These findings suggest poorer immune function towards donor-induced strains of CMV versus recipient own latent strains.


Subject(s)
Cytomegalovirus Infections/immunology , Cytomegalovirus/immunology , Organ Transplantation/adverse effects , Tissue Donors , Adolescent , Adult , Antibodies, Viral/blood , Antiviral Agents/therapeutic use , Child , Cohort Studies , Cytomegalovirus/pathogenicity , Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/etiology , Denmark/epidemiology , Female , Follow-Up Studies , Ganciclovir/therapeutic use , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Retrospective Studies , Risk Factors , Seroepidemiologic Studies , Young Adult
3.
J Am Coll Cardiol ; 53(23): 2162-7, 2009 Jun 09.
Article in English | MEDLINE | ID: mdl-19497443

ABSTRACT

OBJECTIVES: This study investigated the influence of the mechanical blood pump HeartMate II (HMII) (Thoratec Corporation, Pleasanton, California) on blood coagulation and platelet function. BACKGROUND: HMII is an implantable left ventricular assist device used for the treatment of heart failure. Patients treated with HMII have increased bleeding tendencies. METHODS: We measured agonist-induced platelet aggregation in 16 patients on HMII support. RESULTS: The von Willebrand factor (vWF)-dependent ristocetin-induced platelet aggregation was impaired in 11 of the 16 patients, of which 12 had experienced at least 1 minor or major bleeding episode. The impaired ristocetin-induced platelet aggregation was associated both with decreased specific activity of plasma vWF, presumably due to lack of high molecular weight vWF multimers, as well as with attenuated function of the platelets themselves. CONCLUSIONS: The results imply that HMII treatment is associated with impaired platelet aggregation, which may contribute to an increased tendency to bleed.


Subject(s)
Blood Platelets , Heart Failure/therapy , Heart-Assist Devices/adverse effects , Platelet Aggregation , Ventricular Dysfunction, Left/therapy , von Willebrand Factor/physiology , Adult , Anti-Bacterial Agents/adverse effects , Female , Hemorrhage/etiology , Hemorrhage/physiopathology , Hemorrhage/prevention & control , Humans , International Normalized Ratio , Male , Middle Aged , Platelet Aggregation Inhibitors , Ristocetin/adverse effects , Stroke Volume , Ventricular Function, Left , Young Adult
4.
Comp Biochem Physiol B Biochem Mol Biol ; 131(3): 475-82, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11959029

ABSTRACT

The formation of N-acyl-ethanolamines (NAEs), including the cannabinoid receptor ligand anandamide, and their precursors N-acyl-ethanolamine phospholipids (NAPEs) are catalyzed by NAPE-hydrolyzing phospholipase D (NAPE-PLD) and N-acyl-transferase, respectively. NAPE and NAE are suggested to have beneficial effects on the heart, but in the literature there are indications of species differences in the activity of these enzymes. We have examined heart microsomes from rats, mice, guinea pigs, rabbits, frogs, cows, dogs, cats, mini pigs and human beings for activities of these two enzymes. N-Acyl-transferase activity was very high in dogs and cats (>13 pmol/min/mg protein) whereas it was very low to barely detectable in the other species (<3 pmol/min/mg protein). NAPE-PLD activity was very high in rats and guinea pigs (>45 pmol/min/mg protein) whereas it was 9 pmol/min/mg protein in frogs and below that in the other species. The ratio of activity between the two enzymes varied from 0.002 to 15 in the investigated species. The activity of the two enzymes in rat hearts as opposed to rat brain did not change during development. These results indicate that there may be substantial species differences in the generation of anandamide and other NAEs as well as NAPEs in heart tissues.


Subject(s)
Acyltransferases/metabolism , Myocardium/enzymology , Phosphatidylethanolamines/metabolism , Phospholipase D/metabolism , Animals , Brain/growth & development , Brain/metabolism , Cats , Cattle , Dogs , Female , Guinea Pigs , Male , Mice , Microsomes/enzymology , Rabbits , Rats , Rats, Sprague-Dawley , Species Specificity , Swine , Xenopus laevis
5.
J Heart Lung Transplant ; 21(2): 211-6, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11834349

ABSTRACT

BACKGROUND: The incidence of cardiac allograft vasculopathy increases with time after heart transplantation. Allograft vasculopathy is associated with endothelial dysfunction and reduced endothelium-dependent nitric oxide-mediated vascular effects. In this study, temporal changes in endothelial nitric oxide synthase (NOS3) expression in human myocardial biopsies were investigated during the first 3 years after heart transplantation. METHODS: In each patient (n = 7), the immunohistochemical presence of NOS3 and inducible nitric oxide synthase were examined in serial biopsies taken at 1, 4, and 26 weeks and at 1, 2, and 3 years after transplantation. RESULTS: Endothelial nitric oxide synthase was present in vascular endothelial cells in all biopsies at the time of transplantation. A rapid fall within the first months in the number of NOS3-positive biopsies was observed, with a possible difference in the rate of disappearance among the capillaries, the arterial endothelium, and the venous endothelium. After 2 years, very little NOS3 could be detected. Inducible nitric oxide synthase was present in vascular smooth muscle cells throughout the study period and did not change. CONCLUSION: Endothelial nitric oxide synthase immunoreactivity is gradually lost after heart transplantation. These changes may be responsible for the coronary endothelial dysfunction often seen after human cardiac transplantation.


Subject(s)
Endothelium, Vascular/enzymology , Heart Transplantation , Myocardium/enzymology , Nitric Oxide Synthase/biosynthesis , Temporal Arteries/enzymology , Adult , Biopsy , Child, Preschool , Denmark , Endothelium, Vascular/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myocardium/pathology , Temporal Arteries/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...